Bioavailability of aspirin and salicylamide following oral co-administration in human volunteers

TY - JOUR

T1 - Bioavailability of aspirin and salicylamide following oral co-administration in human volunteers

AU - Abdel-Rahman, M. S.

AU - Reddi, A. S.

AU - Curro, F. A.

AU - Turkall, R. M.

AU - Kadry, A. M.

AU - Hansrote, J. A.

PY - 1991

Y1 - 1991

N2 - BC® powder (I) is a commercially available analgesic containing the active ingredients aspirin and salicylamide. The kinetics of I, BC® powder minus aspirin (II), and BC® powder minus salicylamide (III) were evaluated in 13 volunteers. Ten minutes after administration of I, aspirin reached a maximum concentration of 12.9 μg/mL, while salicylamide concentration reached a peak value of 3.4 μg/mL However, when III was administered, aspirin was not detected at 10 min and only reached a concentration of 0.4 μg/mL at 2 and 6 h. Furthermore, the area under the plasma concentration versus time curve for aspirin when III was administered was sixfold less compared with treatment with I. The area under the curve for aspirin metabolites was significantly different in I versus III. After treatment with II, a delay in salicylamide peak concentration was observed. Gentisamide was not detected throughout the study. This study demonstrates that salicylamide significantly enhances plasma levels of aspirin with potential therapeutic implications.

AB - BC® powder (I) is a commercially available analgesic containing the active ingredients aspirin and salicylamide. The kinetics of I, BC® powder minus aspirin (II), and BC® powder minus salicylamide (III) were evaluated in 13 volunteers. Ten minutes after administration of I, aspirin reached a maximum concentration of 12.9 μg/mL, while salicylamide concentration reached a peak value of 3.4 μg/mL However, when III was administered, aspirin was not detected at 10 min and only reached a concentration of 0.4 μg/mL at 2 and 6 h. Furthermore, the area under the plasma concentration versus time curve for aspirin when III was administered was sixfold less compared with treatment with I. The area under the curve for aspirin metabolites was significantly different in I versus III. After treatment with II, a delay in salicylamide peak concentration was observed. Gentisamide was not detected throughout the study. This study demonstrates that salicylamide significantly enhances plasma levels of aspirin with potential therapeutic implications.

KW - BC® powder

KW - aspirin

KW - bioavailability

KW - salicylamide

UR - http://www.scopus.com/inward/record.url?scp=0026316797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026316797&partnerID=8YFLogxK

U2 - https://doi.org/10.1139/y91-215

DO - https://doi.org/10.1139/y91-215

M3 - Article

C2 - 1777842

SN - 0008-4212

VL - 69

SP - 1436

EP - 1442

JO - Canadian Journal of Physiology and Pharmacology

JF - Canadian Journal of Physiology and Pharmacology

IS - 10

ER -